New growth hormone approved for short kids

Insmed Inc. has received the green light from the FDA for iPlex (mecasermin rinfabate [rDNA origin] injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. According to the Richmond, Va., firm, iPlex is the only approved once-daily IGF-1 replacement therapy available to treat children with short stature.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.